Urology dpt, First Affiliated Hospital of Nanjing Medical University
Welcome,         Profile    Billing    Logout  
 0 Trials 
1 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hua, Lixin
NCT04691804 / 2020-006063-28: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting
3
496
Europe, US, RoW
Fuzuloparib , Abiraterone acetate and Prednisone, SHR3162, Fuzuloparib Placebo， Abiraterone acetate and Prednisone
Jiangsu HengRui Medicine Co., Ltd.
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
12/26
12/26
Hua, Lixxin
No trials found
Wang, Shangqian
No trials found

Download Options